Human Microbiome Market Outlook 2028

1. Human Microbiome Market Outlook 2028 The globalhuman microbiome market was valued at US$1.3 Bn in 2020 It is estimated to expand at a CAGR of 7.1% from 2021 to 2028 The globalhuman microbiome market isexpected to reach the value of US$2.2 Bn by the end of 2028    Analysts’ Viewpoint on Human Microbiome Market Scenario Increasing gastrointestinal disorders, technological advancements, rising investments in human microbiome projects in developing countries, and lucrative presence of market players across the globe are factors responsible for the rapid expansion of global human microbiome market. The growing awareness about women health is also driving the global human microbiome market. Market stakeholders are extending their services arms by developing innovative and technologically advanced products in order to gain revenue benefits. Market players operating in the global human microbiome market should focus on the challenges associated with the clinical trial setbacks, some regulatory hurdles, and privacy Issues in diagnostics to stay afloat in the business. In addition, companies in the global human microbiome market should accelerate their product development and unlock revenue opportunities to obtain competitive benefits. Increase in Research & Development Activities in Human Microbiome Market Microbiome is a genetic component of various microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body. The rising knowledge about the benefits of the bacteria present in the microbiome for better digestion of food, regulation of the immune system, and protection against other disease-causing bacteria is fueling the growth of the global human microbiome market. Manufacturers operating in the global human microbiome market are developing diagnostic and therapeutic products. The increasing research & development activities in the field of human microbiome market is contributing to the growth of the global human microbiome market. Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing simple and cost-effective, paving the way to carry out rapid analysis of the genomic content of microorganisms from human sample. This has strengthened the development process for microbiome-based diagnostics. Gastrointestinal and metabolic disorders are likely to capture the leading share of the diagnostics market. Due to rise in focus of companies toward developing an easy analysis platform for gut health-based disorders, such as irritable bowel syndrome and Crohn’s disease. Rising efforts by manufacturers to develop non-invasive tests create potential opportunities for market growth.

2. Request https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999 Sample: Metagenomic Sequencing Technology Generates Lucrative Revenue Benefits for Manufacturers Among technologies, the global human microbiome market has been divided into metagenomic sequencing and 16s rRNA sequencing. The metagenomic sequencing segment is expected to account for the largest share of the global human microbiome market. This growth can be attributed to the rising penetration of small-scale product manufacturers across the globe. These players are engaged in providing comprehensive data profiles of the inherent microbiome of the individual being tested. There is rising investments by companies operating in the human microbiome market. Increasing partnerships and collaborative activities by market players to offer technology-driven products is anticipated to propel the segment during the forecast period. Rising Prevalence of Gastrointestinal and Metabolic Disorders Drive Market Growth The growth of the global human microbiome market can be attributed to the increasing prevalence of gastrointestinal & metabolic disorders. The growing awareness about the severity of chronic diseases such as cancer driving the expansion of the global human microbiome market. Major market players in the microbiome diagnostics segment are launching innovative products to cure several common gut problems, Crohn’s disease, and ulcerative colitis. The growth of the segment can be attributed to the high number of microbiome diagnostic companies and ease of non- invasive testing provided by this method. Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Microbiome Market Tremendous Growth Opportunities for North America Market Players Due to the increase in investments in research & development, ongoing clinical trials for developing microbiome-based therapies, stringent governmental regulations, and rapid technological advancements, North America is expected to dominate the global human microbiome market in the upcoming years. The growing awareness about the benefits of microbiome-based products in consumers is escalating the demand for these products. A large number of market players working in the North America is a major driving factor for the. The increasing efforts by governments to promote human

3. microbiome products is contributing to the expansion of the North America human microbiome market, creating value-grab opportunities for market players. Human Microbiome Market: Overview According to Transparency Market Research’s latest report on the global human microbiome market for the historical period 2017–2019 and forecast period 2021–2028, technological advancements, mergers & collaborations, rise in venture capital investments, and surge in financing of the microbiome projects are projected to drive the global human microbiome market during the forecast period  Increase in Industry-Institute Partnerships and High Unmet Medical Needs to Drive Global Market Significant number of microbiome therapeutics and diagnostics are targeted toward a market with large unmet medical needs. For instance, the present standard of care for Clostridium difficile infection (CDI) is a treatment with antibiotics. Antibiotic treatment can resolve acute infection; however, it also has the probability to worsen dysbiosis in patients. This makes them potentially more susceptible to recurrence of CDI. Patients with recurrent CDI receive many rounds of antibiotics that could worsen dysbiosis, and hence, are more likely to face a relapse. Various key companies strives to resolve unmet medical needs for cancer, CNS disorders, women’s health disorders, skin disorders, and rare diseases through their microbiome-based products. The human microbiome is still an emerging and extensive science. Collaborating with eminent scientists, researchers, and physicians in the field helps in enhancing a company’s go-to-market strategy. Industry-institute partnerships are thriving in the microbiome market and fueling growth. For instance, in 2020, Enterome collaborated with BIOASTER Institute to explore the mechanism of cancer immunotherapies that are microbiome derived.   Clinical Trial Setbacks, Regulatory Hurdles, and Privacy Issues in Diagnostics to Hamper Market The global microbiome market is in its nascent stage. Hence, the likelihood of unfavorable results from a clinical trial is a risk that could hamper market growth. For instance, in 2016, Seres Therapeutics suffered a setback as its microbiome therapeutic SER-109 failed to overtake a placebo for reducing the risk of Clostridium difficile infection (CDI). However, the company is backed by a strong research team and aims to find a solution to the hurdle soon. Therefore, despite minor setbacks, expertise and advances in the microbiome market can help to offset the restraint. Concerns over privacy of subjects and sending stool or other samples for diagnostic testing are likely to restrain the global market. To draw an analogy, it is similar to the concern over 23andme’s genetic tests, where there were concerns in public regarding privacy and anonymity of their genetic data.  

4. Request https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3999 Brochure: Human Microbiome Market: Competition Landscape This report profiles major players in the global human microbiome market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments  The global human microbiome market is highly fragmented, with the presence of a number of small, mid-size, and large prominent players  Leading players operating in the global human microbiome market are  oAOBiome oEnterome Biosciences SA oMetabiomics Corp. (BioSpherex LLC) oMicrobiome Therapeutics LLC oOsel, Inc. oRebiotix, Inc. oSecond Genome oSeres Therapeutics oSynthetic Biologics, Inc. oVedanta Biosciences o4D Pharma oFerring Pharmaceuticals, and other prominent players About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real- time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

5. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/